Conversely, genomewide mutation analyses and high-throughput deep sequencing revealed the presence of mutations in either IDH1 or its mitochondrial counterpart IDH2 in 70% of grade II-III gliomas and secondary glioblastomas [24, 25]. Here, IDH2 is linked to glioma.